J
Judith R. Kroep
Researcher at Leiden University Medical Center
Publications - 207
Citations - 8398
Judith R. Kroep is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 44, co-authored 187 publications receiving 6667 citations. Previous affiliations of Judith R. Kroep include Leiden University & VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf,Sabrina Kuttruff-Coqui,Katrin Frenzel,Valesca Bukur,Stefan Stevanovic,Stefan Stevanovic,Cécile Gouttefangeas,Cécile Gouttefangeas,Michael Platten,Michael Platten,Ghazaleh Tabatabai,Ghazaleh Tabatabai,Valérie Dutoit,Sjoerd H. van der Burg,Per thor Straten,Per thor Straten,Francisco Martínez-Ricarte,Berta Ponsati,Hideho Okada,Ulrik Lassen,Arie Admon,Christian H. Ottensmeier,Alexander Ulges,Sebastian Kreiter,Andreas von Deimling,Andreas von Deimling,Marco Skardelly,Denis Migliorini,Judith R. Kroep,Manja Idorn,Manja Idorn,Jordi Rodon,Jordi Rodon,Jordi Piro,Hans Skovgaard Poulsen,Bracha Shraibman,Katy J. McCann,Regina Mendrzyk,Martin Löwer,Monika Stieglbauer,Cedrik M. Britten,David Capper,David Capper,David Capper,Marij J. P. Welters,Juan Sahuquillo,Katharina Kiesel,Evelyna Derhovanessian,Elisa Rusch,Lukas Bunse,Lukas Bunse,Colette Song,Sandra Heesch,Claudia Wagner,Alexandra Kemmer-Brück,Jorg Ludwig,John C. Castle,Oliver Schoor,Arbel D. Tadmor,Edward W. Green,Jens Fritsche,Miriam Meyer,Nina Pawlowski,Sonja Dorner,Franziska Hoffgaard,Bernhard Rossler,Dominik Maurer,Toni Weinschenk,Carsten Reinhardt,Christoph Huber,Hans-Georg Rammensee,Hans-Georg Rammensee,Harpreet Singh-Jasuja,Ugur Sahin,Pierre-Yves Dietrich,Wolfgang Wick,Wolfgang Wick +76 more
TL;DR: In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.
Journal ArticleDOI
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Sant P. Chawla,Robert M. Henshaw,Leanne L. Seeger,Edwin Choy,Jean-Yves Blay,Stefano Ferrari,Judith R. Kroep,Robert J. Grimer,Peter Reichardt,Piotr Rutkowski,Scott M. Schuetze,Keith M. Skubitz,Arthur P. Staddon,David Thomas,Yi Qian,Ira Jacobs +15 more
TL;DR: Denosumab was associated with tumour responses and reduced the need for morbid surgery in patients with GCTB and represents a new treatment option for patients with the rare giant cell tumour of bone.
Journal ArticleDOI
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Jakob K. Anninga,Hans Gelderblom,Marta Fiocco,Judith R. Kroep,Antoni H. M. Taminiau,Pancras C.W. Hogendoorn,R. Maarten Egeler +6 more
TL;DR: Meta-analysis in patients with localised high-grade osteosarcoma shows that 3-drug regimens, for example MAP are the most efficacious drug regimens and Salvage of poor responders by changing drugs, or intensifying treatment postoperatively has not proven to be useful.
Journal ArticleDOI
Basis for effective combination cancer chemotherapy with antimetabolites.
Godefridus J. Peters,C.L. van der Wilt,C.J.A. van Moorsel,Judith R. Kroep,Andries M. Bergman,Stephen P. Ackland +5 more
TL;DR: The median-drug effect analysis method is one of the most widely used methods for in vitro evaluation of combinations, and several examples of classical effective antimetabolite-(anti)metabolite combinations are discussed, such as that of methotrexate with 6-mercaptopurine or leucovorin in (childhood) leukemia.
Journal ArticleDOI
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment
Eveline M. Dijkgraaf,Moniek Heusinkveld,Bart Tummers,Lisa T.C. Vogelpoel,Renske Goedemans,Veena Jha,Johan W. R. Nortier,Marij J. P. Welters,Judith R. Kroep,Sjoerd H. van der Burg +9 more
TL;DR: Concomitant therapy with COX inhibitors and/or IL-6R antibodies might increase the clinical effect of platinum-based chemotherapy in otherwise resistant tumors, suggesting that a chemotherapy-mediated increase in tumor-promoting M2 macrophages may form an indirect mechanism for chemoresistance.